Soleus Capital Management, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001802630
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 97 positions · Total reported value $2.90B · Top-10 concentration 48.9% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 70.2% · 21 new · 42 cut · 17 exited
Active Share (vs S&P 500): 99.3% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +24.8% · vs SPY +9.9% · Prev Value $2.47B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Soleus Capital Management, L.P. disclosed 97 equity positions with a combined reported value of $2.90B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were KRYS ($349.09M), CELC ($178.31M), TGTX ($160.86M). By sector, the heaviest allocations are Health Care 98.4%, Technology 0.3%.
Versus the prior quarter, Soleus Capital Management, L.P. opened 21 new positions, trimmed 42 and fully exited 17, a turnover rate of 70.2% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q2 2026 were ERAS ($49.46M), PBLS ($40.10M), LEGN ($34.80M).
Of the 17 positions fully exited versus the prior quarter, the largest were PCVX ($22.40M), ICLR ($21.25M), TVTX ($16.22M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- PCVX VAXCYTE INC · prev qtr: $22.40M
- ICLR ICON PLC · prev qtr: $21.25M
- TVTX TRAVERE THERAPEUTICS INC · prev qtr: $16.22M
- INBX INHIBRX BIOSCIENCES INC · prev qtr: $8.81M
- DXCM DEXCOM INC COM · prev qtr: $8.79M
- ETON ETON PHARMACEUTICALS INC · prev qtr: $4.11M
- ARWR ARROWHEAD PHARMACEUTICALS IN · prev qtr: $1.79M
- CTMX CYTOMX THERAPEUTICS INC · prev qtr: $1.41M
Insider Transactions (Form 4)
Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 527,070 | $9.48 | SEC filing |
| 2026-06-11 | Buy | Parabilis Medicines, Inc. | 125,000 | $20.00 | SEC filing |
| 2026-06-11 | Buy | Parabilis Medicines, Inc. | 375,000 | $20.00 | SEC filing |
Fund Profile
Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q2 2026 it reported 97 US equity positions with a combined value of $2.90B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: GREENWICH, CT, United States
- SEC registration: 801-118942 (status: Approved), registered 2020-06-25
- Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 12 private funds, of which 1 hedge funds
Portfolio Structure
- 97 positions · $2.90B reported value (Q2 2026)
- Top 10 holdings = 48.9% of reported value
- Largest position: KRYS (KRYSTAL BIOTECH INC) at 12.0%
- Average position size: $29.92M
Sector Tilt
- Health Care 98.4%
- Information Technology 0.3%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 21 new, 25 added, 42 reduced, 17 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
939.25K | $349.09M | 12.03% | Reduce | |
| 2 |
|
1.70M | $178.31M | 6.14% | Add | |
| 3 |
|
2.93M | $160.86M | 5.54% | Reduce | |
| 4 |
|
1.05M | $159.71M | 5.50% | Add | |
| 5 |
|
9.91M | $150.19M | 5.17% | Reduce | |
| 6 |
|
225.59K | $122.23M | 4.21% | Add | |
| 7 |
|
1.93M | $86.16M | 2.97% | Add | |
| 8 |
|
1.84M | $72.12M | 2.48% | Add | |
| 9 |
|
867.76K | $71.83M | 2.48% | Add | |
| 10 |
|
4.39M | $68.85M | 2.37% | Add | |
| 11 |
|
1.46M | $64.92M | 2.24% | Reduce | |
| 12 |
|
177.52K | $59.43M | 2.05% | Reduce | |
| 13 |
|
42.81M | $54.80M | 1.89% | Add | |
| 14 |
|
1.03M | $53.93M | 1.86% | Reduce | |
| 15 |
|
2.70M | $49.46M | 1.70% | New | |
| 16 |
|
2.91M | $46.26M | 1.59% | Reduce | |
| 17 |
|
1.60M | $46.19M | 1.59% | Reduce | |
| 18 |
|
1.06M | $43.66M | 1.50% | Reduce | |
| 19 |
|
1.47M | $40.10M | 1.38% | New | |
| 20 |
|
7.31M | $37.86M | 1.30% | Hold | |
| 21 |
|
468.92K | $37.05M | 1.28% | Reduce | |
| 22 |
|
1.17M | $36.03M | 1.24% | Add | |
| 23 |
|
1.63M | $35.59M | 1.23% | Reduce | |
| 24 |
|
1.47M | $35.54M | 1.23% | Add | |
| 25 |
|
1.21M | $34.80M | 1.20% | New | |
| 26 |
|
1.55M | $34.46M | 1.19% | Add | |
| 27 |
|
80.00K | $33.25M | 1.15% | New | |
| 28 |
|
1.65M | $30.58M | 1.05% | Add | |
| 29 |
|
829.81K | $30.54M | 1.05% | Add | |
| 30 |
|
515.28K | $28.44M | 0.98% | Add | |
| 31 |
|
13.06M | $27.30M | 0.94% | New | |
| 32 |
|
730.91K | $25.27M | 0.87% | Add | |
| 33 |
|
10.14M | $24.64M | 0.85% | Add | |
| 34 |
|
520.00K | $24.19M | 0.83% | New | |
| 35 |
|
1.00M | $22.65M | 0.78% | Add | |
| 36 |
|
709.00K | $22.16M | 0.76% | Add | |
| 37 |
|
10.88M | $22.08M | 0.76% | Hold | |
| 38 |
|
1.18M | $22.00M | 0.76% | Reduce | |
| 39 |
|
375.57K | $21.49M | 0.74% | Reduce | |
| 40 |
|
254.96K | $20.97M | 0.72% | Reduce | |
| 41 |
|
19.95K | $18.51M | 0.64% | Add | |
| 42 |
|
1.00M | $18.39M | 0.63% | New | |
| 43 |
|
761.74K | $18.34M | 0.63% | New | |
| 44 |
|
450.89K | $18.32M | 0.63% | Reduce | |
| 45 |
|
3.38M | $18.01M | 0.62% | New | |
| 46 |
|
267.00K | $16.12M | 0.56% | Reduce | |
| 47 |
|
3.38M | $15.78M | 0.54% | Reduce | |
| 48 |
|
246.35K | $15.75M | 0.54% | Reduce | |
| 49 |
|
732.14K | $14.01M | 0.48% | Add | |
| 50 |
|
419.00K | $13.79M | 0.47% | New | |
Loading forecast…
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)
Historical Backtest (10 quarters)
Avg precision 59% · recall 59% · F1 59% · avg rank error 2.9 · Top-10 turnover 39%
| Quarter | Prec. | Recall | F1 | Predicted Top 10 | Actual Top 10 |
|---|---|---|---|---|---|
| 2024-Q1 | 50% | 50% | 50% | TEVA · UTHR · RYZB · GSK · FOCL · ORGO · HUM · CELC · IRMD · EPIX | XBI · UTHR · FOCL · IOVA · TEVA · TGTX · CELC · JSPR · NPCE · EPIX |
| 2024-Q2 | 50% | 50% | 50% | XBI · UTHR · IOVA · TGTX · FOCL · TEVA · CELC · NPCE · JSPR · EPIX | TGTX · IOVA · UTHR · NRIX · FOCL · TERN · RVMD · SRDX · ORGO · JSPR |
| 2024-Q3 | 50% | 50% | 50% | TGTX · IOVA · NRIX · UTHR · FOCL · RVMD · TERN · ORGO · SRDX · KRYS | XBI · IOVA · TGTX · TERN · AXGN · GRFS · KRYS · CCCC · UTHR · SNY |
| 2024-Q4 | 70% | 70% | 70% | IOVA · XBI · TGTX · TERN · KRYS · CCCC · AXGN · GRFS · SNY · IDYA | XBI · NVCR · TGTX · BMRN · KRYS · GRFS · AXGN · IOVA · TEVA · TERN |
| 2025-Q1 | 60% | 60% | 60% | XBI · NVCR · TGTX · BMRN · KRYS · GRFS · TEVA · AXGN · IOVA · TERN | XBI · TGTX · NVCR · KRYS · BMRN · ORGO · GRFS · UTHR · STAA · PRAX |
| 2025-Q2 | 90% | 90% | 90% | XBI · TGTX · NVCR · KRYS · BMRN · ORGO · GRFS · UTHR · PRAX · STAA | KRYS · NVCR · TGTX · XBI · UTHR · BBNX · GRFS · STAA · BMRN · ORGO |
| 2025-Q3 | 60% | 60% | 60% | KRYS · NVCR · TGTX · UTHR · BBNX · XBI · STAA · GRFS · BMRN · PRAX | KRYS · TGTX · NVCR · XBI · ELV · BBNX · UTHR · TERN · CELC · INSP |
| 2025-Q4 | 50% | 50% | 50% | KRYS · TGTX · NVCR · XBI · ELV · BBNX · UTHR · INSP · TERN · TWST | XBI · KRYS · CELC · NVCR · PRAX · TGTX · DXCM · BMRN · GMED · BBNX |
| 2026-Q1 | 50% | 50% | 50% | XBI · KRYS · CELC · NVCR · TGTX · PRAX · GMED · DXCM · FOLD · BMRN | KRYS · CELC · TGTX · PODD · NVCR · UTHR · PRAX · VCEL · ALKS · ANIP |
| 2026-Q2 ★ | 60% | 60% | 60% | KRYS · CELC · TGTX · PODD · UTHR · NVCR · PRAX · VCEL · ALKS · GMED | KRYS · CELC · TGTX · PODD · NVCR · UTHR · INSP · RIGL · ANIP · BBNX |
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
FAQ
What did Soleus Capital Management, L.P. buy in 2026-Q2?
In its 2026-Q2 13F filing, Soleus Capital Management, L.P. reported 97 equity positions worth $2.90B in aggregate; its largest disclosed positions were KRYS ($349.09M), CELC ($178.31M), TGTX ($160.86M).
How large is Soleus Capital Management, L.P.'s portfolio?
Soleus Capital Management, L.P. reported $2.90B of long equity holdings across 97 positions as of 2026-Q2. Top-10 holdings account for 48.9% of reported value.
What is Soleus Capital Management, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.